Mirum Pharmaceuticals (NASDAQ:MIRM) insider Edwin Jonathan Tucker bought 2,000 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was purchased at an average price of $9.91 per share, for a total transaction of $19,820.00. Following the completion of the acquisition, the insider now owns 3,500 shares in the company, valued at $34,685. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of NASDAQ:MIRM opened at $12.43 on Thursday. The company has a current ratio of 9.13, a quick ratio of 9.13 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $15.03 and its two-hundred day simple moving average is $13.19. Mirum Pharmaceuticals has a 1-year low of $6.51 and a 1-year high of $28.31. The stock has a market cap of $314.58 million and a PE ratio of -2.71.
Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.06. On average, sell-side analysts forecast that Mirum Pharmaceuticals will post -3.38 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in MIRM. Boxer Capital LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $7,773,000. Millennium Management LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $1,261,000. EAM Global Investors LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $1,484,000. EAM Investors LLC purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth about $1,147,000. Finally, Geode Capital Management LLC increased its holdings in Mirum Pharmaceuticals by 178.1% in the 4th quarter. Geode Capital Management LLC now owns 58,568 shares of the company’s stock worth $1,436,000 after acquiring an additional 37,510 shares during the last quarter. 64.01% of the stock is owned by hedge funds and other institutional investors.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.